NASDAQ:CHMA
Delisted

Chiasma Stock Insider Trading

etoro logo Buy CHMA
*Your capital is at risk
$3.76
+0 (+0%)
At Close: May 27, 2022

Chiasma Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 CHMA shares in the last 0 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CHIASMA
Chiasma
Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massa...
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
13.43% Jun 05
TPR
$140.47
4.95% Jun 04
LITE
$905.00
1.83% Jun 01
RUN
$12.83
0.468% May 06
GLBE
$31.61
3.54% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE